Diabetes and endothelial dysfunction: a clinical perspective

Area of Science:

• Cardiovascular Science
• Endocrinology
• Metabolic Disorders

Background:

• Atherosclerosis is the primary cause of mortality and morbidity in diabetes mellitus.
• Endothelial dysfunction, characterized by altered signaling or nitric oxide bioavailability, is hypothesized as an initial atherosclerotic lesion.
• This dysfunction is observed in patients with diabetes, insulin resistance, and those at high risk for type 2 diabetes.

Purpose of the Study:

• To review the role of endothelial dysfunction in diabetes-related atherosclerosis.
• To evaluate the efficacy of various therapeutic interventions on endothelial function in diabetic patients.

Main Methods:

• Literature review of clinical trials and studies investigating endothelial function in diabetes.
• Analysis of factors contributing to endothelial dysfunction in diabetes, including protein kinase C activation, growth factor/cytokine overexpression, and oxidative stress.
• Assessment of therapeutic interventions such as insulin sensitizers, ACE inhibitors, hypolipidemic agents, antioxidant therapy, and hormone replacement therapy.

Main Results:

• Insulin sensitizers may offer short-term improvements, but cardiovascular endpoint data are lacking.
• ACE inhibitors show promise in potentially slowing atherosclerosis progression.
• The impact of hypolipidemic agents is unclear, antioxidant therapy is controversial, and hormonal replacement therapy data is absent for postmenopausal women with type 2 diabetes.

Conclusions:

• Endothelial dysfunction is a critical factor in diabetes-related atherosclerosis.
• Further research with cardiovascular endpoints is needed to confirm the long-term benefits of therapeutic interventions.
• Targeting endothelial dysfunction presents a potential strategy for managing cardiovascular complications in diabetes.